Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTS · Real-Time Price · USD
7.30
-0.61 (-7.71%)
At close: Apr 28, 2026, 4:00 PM EDT
7.90
+0.60 (8.22%)
After-hours: Apr 28, 2026, 7:25 PM EDT
Company Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.
Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
The company is headquartered in Jerusalem, Israel.
Alpha Tau Medical Ltd.
| Country | Israel |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 121 |
| CEO | Uzi Sofer |
Contact Details
Address: Kiryat HaMada St. 5 Jerusalem, 9777605 Israel | |
| Phone | 972 3 577 4115 |
| Website | alphatau.com |
Stock Details
| Ticker Symbol | DRTS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001871321 |
| CUSIP Number | M0740A108 |
| ISIN Number | IL0011839383 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Uzi Sofer | Chief Executive Officer and Chairman |
| Raphi Levy | Chief Financial Officer |
| Amnon Gat | Chief Operations Officer |
| Ronen Segal | Chief Technology Officer |
| Dr. Robert B. Den M.D. | Chief Medical Officer and Member of Scientific Advisory Board |
| Prof. Yona Keisari | Chief Scientific Officer and Member of Scientific Advisory board |
| Rebecca Becker | Vice President of legal |
| Yael Zeiger | Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | F-3 | Filing |
| Apr 27, 2026 | 6-K | Report of foreign issuer |
| Apr 23, 2026 | 6-K | Report of foreign issuer |
| Mar 31, 2026 | 6-K | Report of foreign issuer |
| Mar 9, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 9, 2026 | 6-K | Report of foreign issuer |
| Mar 9, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Feb 26, 2026 | 144 | Filing |
| Feb 24, 2026 | 6-K | Report of foreign issuer |
| Feb 2, 2026 | 144 | Filing |